Innovative WEF-style forums will gather experts from the corporate, neuroscience, and clinical fields to discuss breakthroughs in neurodegeneration research. These sessions aim to advance our understanding and treatment of Alzheimer’s and Parkinson’s diseases by exchanging new insights and addressing current challenges. Each forum features brief introductions by participants, followed by an audience Q&A, with media coverage to share progress in the field.
Tuesday, March 16, 2027
Global Leadership Forum
MOONSHOTS & MILESTONES: AFTER AMYLOID—WHO WILL OWN THE FUTURE OF NEURODEGENERATION: THERAPIES, BIOMARKERS, OR AI?
Roger Nitsch
Henrietta Nielsen
Wednesday, March 17, 2027
Forum
BIOMARKERS THAT DECIDE: ARE WE READY TO TREAT BEFORE SYMPTOMS?
Melissa Murray
Henrik Zetterberg
Forum
AI → IMPACT: CAN DATA-DRIVEN BIOLOGY DELIVER REAL DISEASE-MODIFYING THERAPIES?
Rhoda Au
Randall Bateman
Thursday, March 18, 2027
Forum
OPTIMISING THERAPY: PROMISING COMBINATION STRATEGIES IN AD AND PD
Jeffrey Cummings
Laura Nisenbaum
Forum
REWIRING THE FAILING BRAIN: CAN CIRCUIT-BASED THERAPIES DELIVER THE NEXT GENERATION OF CNS DRUGS?
Manfred Windisch
Taylor Schmitz
Friday, March 19, 2027
Forum
PRECISION NEUROLOGY: MATCHING THE RIGHT DRUG TO THE RIGHT PATIENT—FROM BIOMARKERS TO CLINICAL REALITY
Tamara Shiner
Giovanni Frisoni
Forum
BIOMARKERS AND DISEASE MODIFICATION IN PD: TARGETING ALPHA-SYNUCLEIN, LRRK2 AND GBA.
Jamie Eberling
Ken Mark
Saturday, March 20, 2027
Forum
MICROGLIA IN COMMAND: REPROGRAMMING THE BRAIN–IMMUNE AXIS—BREAKTHROUGHS, TARGETS, AND RISKS
Cynthia Lemere
David Holtzman